

This is a repository copy of *Update: Homing of Mesenchymal Stem Cells*.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/123785/>

Version: Accepted Version

Article:

Kehoe, Oksana, Fox, James Martin orcid.org/0000-0002-2473-7029 and Middleton, Jim (2017) Update: Homing of Mesenchymal Stem Cells. *Stem Cells*. ISSN 1066-5099

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.

STEM CELLS

Anniversary Collection: 35 Years of **STEM CELLS**

Table of Contents

Homing of Mesenchymal Stem Cells

Oksana Kehoe^a, James Fox^b and Jim Middleton^c^aRheumatology Research Laboratory, School of Medicine and ISTM, Keele University at RJA Orthopaedic Hospital, Oswestry, United Kingdom^bDepartment of Biology, University of York, York, United Kingdom^cSchool of Oral and Dental Sciences, University of Bristol, Bristol, United Kingdom**An Update to: Concise Review: Mesenchymal Stem Cells: Their Phenotype, Differentiation Capacity, Immunological Features, and Potential for Homing**

Giselle Chamberlain, James Fox, Brian Ashton, and Jim Middleton

Stem Cells 2007;25:2739–2749

Mesenchymal stem cells (MSCs) show therapeutic potential in preclinical inflammatory disease models and in some clinical trials in patients with Crohn's disease, diabetes, stroke, cartilage and bone injury, graft-versus-host disease (GVHD), and myocardial infarction [1]. The definition of MSC phenotype has evolved and the International Society for Cellular Therapy recommends a number of assays to standardize MSCs for clinical trials based on their immunomodulatory properties [2].

One problem facing MSC usage for diseased tissue regeneration is the low level of recruitment and retention of cells in affected tissues; typically, less than 1% of systemically injected MSCs reach their target. Deficient MSC homing is usually attributed to an absence of relevant cell-surface homing molecules classically expressed by hematopoietic stem cells and leukocytes [3] and potentially due to MSC heterogeneity [4]. Several recent in vitro studies investigated mechanisms of MSC transendothelial migration and the effects of chemokines and shear stress [5, 6–7]. MSC adhesion and transmigration increased upon activation of endothelium with TNF- α , and chemokines CXCL9, CXCL16, CCL20, and CCL25 enhanced MSC firm adhesion, crawling, and spreading. Shear-resistant arrest of MSCs on endothelial cell surfaces occurred when cells were left under shear-free conditions for several minutes before flow was reinstated; no interactions were observed under conditions of constant shear flow [5]. The results of this study are in line with previously proposed passive and active homing for MSCs

[3]. MSCs may become passively arrested in narrow capillaries leading to chemokine presentation, integrin activation, adhesion, crawling, and spreading before chemoattraction along a chemokine gradient into extravascular tissue. Early MSC transmigration was associated with nonapoptotic membrane blebbing that was previously described for metastatic tumor and embryonic germ cells, whilst some MSCs migrated through discrete endothelial pores and gaps by transcellular and paracellular processes [6]. Aldridge et al. demonstrated that human MSCs were recruited to injured liver in a β 1-integrin- and CD44-dependent manner [7].

MSC homing could potentially be improved by several methods; for example, modification of MSC surface with sialyl LewisX (sLeX) [8], a key mediator of leukocyte rolling, or CXCR4 [9] have both been shown to enhance MSC homing to inflamed tissue. Hypoxic preconditioning of MSCs also increases their recruitment in a mouse focal cerebral ischemia model by upregulating CXCR4, MMP-2, and MMP-9 expression [10].

The recent paradigm shift in MSC utilization for therapy based on their immunomodulatory and anti-inflammatory properties arises from observations that MSC therapy lessened inflammation, fibrosis, and apoptosis in disease models without engraftment in the diseased tissue and differentiation [11]. MSCs may function in immunomodulation predominantly using paracrine mechanisms via growth factor, cytokine, and chemokine secretion and through production of extracellular vesicles (EVs) that contain various proteins, lipids, and nucleic acids, as found in MSC-conditioned medium [12]. The primary advantages of EVs over MSCs are in mitigating safety issues related to living or engineered stem cell therapies.

Advances in our understanding of MSC homing have been made and will likely continue to contribute to improve their clinical efficacy; there is also an appreciation that MSC paracrine effects and EVs might hold promise, but several questions remain.

References

1. Wang LT, Ting CH, Yen ML et al. Human mesenchymal stem cells (MSCs) for treatment towards immune- and inflammation-mediated diseases: Review of current clinical trials. *J Biomed Sci* 2016;23:76.
2. Krampera M, Galipeau J, Shi Y et al. Immunological characterization of multipotent mesenchymal stromal cells—The International Society for Cellular Therapy (ISCT) working proposal. *Cytotherapy* 2013;15:1054–1061.
3. Karp JM, Leng Teo GS. Mesenchymal stem cell homing: The devil is in the details. *Cell Stem Cell* 2009;4:206–216.
4. James S, Fox J, Afsari F et al. Multiparameter analysis of human bone marrow stromal cells identifies distinct immunomodulatory and differentiation-competent subtypes. *Stem Cell Reports* 2015;4:1004–1015.
5. Chamberlain G, Smith H, Rainger GE et al. Mesenchymal stem cells exhibit firm adhesion, crawling, spreading and transmigration across aortic endothelial cells: Effects of chemokines and shear. *PLoS One* 2011;6:e25663.
6. Teo GS, Ankrum JA, Martinelli R et al. Mesenchymal stem cells transmigrate between and directly through tumor necrosis factor- α -activated endothelial cells via both leukocyte-like and novel mechanisms. *STEM CELLS* 2012;30:2472–2486.
7. Aldridge V, Garg A, Davies N et al. Human mesenchymal stem cells are recruited to injured liver in a β 1-integrin and CD44 dependent manner. *Hepatology* 2012;56:1063–1073.
8. Sarkar D, Spencer JA, Phillips JA et al. Engineered cell homing. *Blood* 2011;118:e184–e191.
9. Marquez-Curtis LA, Gul-Uludag H, Xu P et al. CXCR4 transfection of cord blood mesenchymal stromal cells with the use of cationic liposome enhances their migration toward stromal cell-derived factor-1. *Cytotherapy* 2013;15:840–849.
10. Wei N, Yu SP, Gu X et al. Delayed intranasal delivery of hypoxic-preconditioned bone marrow mesenchymal stem cells enhanced cell homing and therapeutic benefits after ischemic stroke in mice. *Cell Transplant* 2013;22:977–991.

11. Ankrum J, Karp JM. Mesenchymal stem cell therapy: Two steps forward, one step back. *Trends Mol Med* 2010;16:203–209.
12. Akyurekli C, Le Y, Richardson RB et al. A systematic review of preclinical studies on the therapeutic potential of mesenchymal stromal cell-derived microvesicles. *Stem Cell Rev* 2015;11:150–160.

Current Issue



Volume 35
Issue 11
November 2017

- [All Issues](#)
- [Browse a free sample issue](#)



Journal Features

- [Virtual Issue: Looking to the Future of Stem Cell Eye Research](#)
- [Young Investigator Award](#)
- [Most Influential Articles](#)

Journal Resources

- [Information for Authors](#)